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SUMMARY
The aim of this research was to evaluate the possible protective effect of pravastatin
on ultrastructural alterations induced by cold stress in the myocardium of rats.
Sixteen EPM-Wistar rats (Rattus norvegicus albinus) were used  and distributed into
four groups: 1) control; 2) pravastatin; 3) cold stress, and  4) pravastatin + cold stress.  A
daily oral dose of 10 mg/kg of weight of pravastatin was administered to each rat in
groups 2 and 4 for 15 days. The stress induced by cold was obtained by keeping the group
3 and 4 rats in a freezer at -8°C for 4 hours. The animals were killed and the heart and
fragments of the left ventricles (LV) were removed and processed prior to conducting
electron microscopic analysis.
The ultrastructural alterations in cardiomyocytes were quantified through the number
of mitochondrial cristae pattern (cristalysis). The group subjected only to cold stress
showed a significant increase in cristalysis (391.9) when compared with control group
(42.0). In the cold stress and pravastatin pretreatment group, a statistically significant
(96.9)*, P<0.05 cristalysis reduction was observed when compared with cold stress group.
The mitochondrial cristalysis profiles of the control and pravastatin groups were 42.0 and
65.7, respectively.
Cold stress induced a significant increase in the rate of mitochondrial cristalysis. In
the group that received pravastatin and was exposed to cold stress, the drug protected the
LV cardiomyocytes. This fact was confirmed by a reduction mitochondrial cristalysis pat-
tern.  (Jpn Heart J 2003; 44: 243-255)
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STRESS is often defined as a threat, real or implied, to homeostasis and  this
term refers to the maintenance of a narrow range of vital physiological parame-
ters necessary for survival.
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Stress represents the effort performed by an organism to adapt or react
against factors that threaten to break the internal steady state.1) More than 60
years ago, Selye recognized that the physiological system was activated by stress,
and that protecting and restoring the body could also damage the system.2)
The physiological response to stress, that is to say the load, must be under-
stood  in terms of a process and not as a static, isolated, and independent reaction,
since the moment in which it begins a prolonged biochemical process occurs
independently of the cause of tension. There are various stressor agents, for
example, physical, chemical, biological or psychological factors, but they always
elicit similar mechanisms of adaptation.1,2)
Allostasis,3) the ability to achieve stability face to changes, as the process for
actively maintaining homeostasis, using the autonomic nervous system (ANS),
the hypothalamo-pituitary-adrenal (HPA), the cardiovascular, metabolic, and
immunological systems to protects the organism against internal and external
stresses.3)
The allostatic response begins with an increase in circulating catechola-
mines from the ANS and glucocorticoids from the adrenal glands. This adaptative
process begins through intracellular receptors for steroid hormones, plasma
membrane receptors, and secondary messengers for catecholamines.  The main-
tenance of the adaptative process can alter the structure and function of a variety
of  cells and tissues.4,5)
Ultrastructural analysis of mitochondria is very important, and as an
organelle which is extremely sensitive to hypoxia, it represents a structure of cen-
tral importance in aerobic metabolism.6) Mitochondria are the powerhouses of the
cell where oxidative phosphorylation takes place to generate ATP. Oxidative
phosphorylation involves the transfer of electrons to oxygen coupled to the syn-
thesis of ATP.  Oxidative stress is the increased generation of free radicals result-
ing in oxidative damage to DNA, proteins, and lipids. Impairment of
mitochondrial oxidative phosphorylation is associated with increased oxidative
stress.7)
The ultrastructural changes in the cardiomyocytes of rats subjected to cold
stress are characterized by myofilament dearrangement, increasing the gap
between mitochondrial cristae sometimes causes erasings, and partial or total rup-
ture of cristae originating in lacular areas.8)
A study in a rat model in which hypoxia was produced through coronary
artery occlusion described focal lesions similar to those described above, pointing
to an acute myocardial hypoxic state produced by the increase in oxygen con-
sumption.9)
The loss of cellular membrane stabilization during hypoxia affects aerobic
respiration, causing a reduction in ATP molecule production and consequently
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activating anaerobic glucolysis, a process which determines lactic acid and inor-
ganic phosphate accumulation and decreases intracellular pH. The decrease in
ATP compromises the Na+ pump mechanism,  an energy-dependent process, with
consequent intracellular Na+ retention and intracellular edema. Diverse effects
have been verified secondary to cold-stress exposure, ie, an increase in catechola-
mine liberation, an increase in the relative disproportion of intracellular calcium,
hypoxia, and ATP depletion act in conjuction in the pathogenesis of ultrastruc-
tural alterations induced in cardiomyocytes.10)
In clinical trials dedicated to the primary11) and secondary12-14) prevention of
coronary heart disease, it was demonstrated that pravastatin modified the actuar-
ial survival curves; after a myocardial infarct the treated group early changes
from the control group. Based on this fact, it was suggested that pravastatin had a
rapid onset protective effect opposed to a slow effect secondary to an action
against progression of the occlusive atherosclerotic plaque process in coronary
arteries.12) The present study was conducted to investigate other possible mecha-
nisms involved in the early protection due to this drug. Since pravastatin is a very
common drug in clinical medicine, the main objective was to evaluate its possible
protective effect against myocardial injury induced by cold. 
MATERIALS AND METHODS
Sixteen adult male EPM-Wistar rats weighing between 250-300 g were
used. The animals were  kept in plastic and metal cages. The room temperature
was kept stable at 22°C, and a circadian rhythm was maintained unaltered. The
animals received food and water ad libitum. After a one week adaptation period,
the animals were selected randomly and assigned to four groups of four animals
each:
Control (CON): received 1 mL of water per os by gastric gavage for 15 consec-
utive days and were kept at normal room temperature.
Pravastatin (PR): received 1 mL of a pravastatin solution (10 mg/kg of weight)
for 15 consecutive days and were kept at normal room temperature.
Stress (ST): received 1 mL of water by gastric gavage for 15 consecutive days
prior to an experimental procedure, and were kept in a freezer for 4 hours at -8C°.
Pravastatin+stress (PR+ST): received 1 mL of a pravastatin solution identical to
the PR group for 15 consecutive days preceding the experiment and were kept in
a freezer for 4 hours at -8°C.
Immediately after light ether anesthesia, the  thorax of each rat was opened
and the heart was exposed and removed. Cold 2% gluteraldehyde solution was
dropped on the still beating heart. Fragments of the left ventricle wall were then
removed and fixed in phosphate buffered glutaraldehyde at pH 7.2. The frag-
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ments were cut into small 1 mm cubic pieces which were postfixed in 1% OsO4
solution for 2 hours at 4C° and then dehydrated and embedded in araldite. Silver
or gray thin sections (60-90 mm) were selected and cut on a Porter-Blum MT-B
ultramicrotome, mounted on copper silver grids with 200 patches, and stained
with uranyl acetate and lead citrate. The samples were selected, collected, and
deposed on copper wire with 200 patches. The preparations were examined with
an electronic microscope (Model EM 90, Carl Zeiss) using a tension of 80 kV.
All electromicrographs were taken under the same  magnification parame-
ters, and their dimensions at the end of the process were 18 × 24 cm (final
amplification × 8,800). The mitochondrial profiles, including the integrity, of the
electron micrographs were analyzed. Mitochondrial lesions (cristalysis) were
defined as a partial or complete lysis of cristae and their substitution by lacunar
areas.
Six electromicrographs of  LV fragments, which were analysed by 3 observ-
ers independently with the same and standardized criteria, were obtained ran-
domly from each group of examined animals. 
Twenty other rats were distributed into four equal groups according to the
same criteria. Total cholesterol (C) and creatine phosphokinase (CPK) levels in
serum were measured.
Statistical analysis: The following tests were used. 1) Analysis of variance with
Kruskal-Wallis15) test to compare the groups among themselves in relation to the
variable: C and CPK levels, number of mitochondria with cristalysis; when any
difference was detected among the groups a test of multiple comparisons was per-
formed.16) 2) To analyse the concordance of measurements performed by three
observers, the index of Bartko for intraclass correlation was used according to the
Fleiss  guidelines.17) This test uses the following formula:
                         N (PMST - EMS)
R=
       N. PMS + (K-1) RMS + (N-1)(K-1) SEM
Where,
PMS = Patients mean square
RMS = Researcher mean square
EMS = Error mean square
     N = number of observed events
 and,
      K = number of observers. 
The formula describes the variability which can occur in each measurement
performed, between the observers, and also the variability due to random error.
When R is higher than 0.75, the concordance between the observers is excellent,
independent of the statistical significance of the results.
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The level of significance was 5%.
RESULTS
The transmission electron  microscopy results for the CON group showed
myocardium fibers and/or elongated and branched cardiomyocytes surrounded
by sarcolemma. There was generally only one nucleus inside the cell usually
located in the central portion  of the fiber. In the sarcoplasm, high concentrations
of mitocondria were observed. Sarcomeres, limited by 2 Z-bands, are composed
of two types of myofilaments; a gross filament composed of myosin, and a thin
filament  composed of actin. They are contained in fascicules called myofibrils.
The mitochondria were dispersed in the sarcoplasma or interposed among abun-
dant myofibrils, characterized by a large number of cristae (Figure 1). 
In the pravastatin group (PR), the cardiomyocytes exhibited a pattern simi-
lar to that of the group of cells belonging to the control group (CON) (Figure 2). 
The stress group (ST) cardiac fibers presented areas of myofibrils well pre-
served, with a structural pattern similar to nomal, and numerous areas with focal
loss of myofibrils. A great number of mitochondria showed different degrees of
Figure 1. Electron micrograph of longitudinal slices of left ventricular cardiomyocytes of rats in the control group (CON).
Note the increased mitochondrial concentration (m). Myofibrils have been cut logitudinally where it is noted the sarcomeres
(S) are delineated by their Z-lines (Bar = 0.5 µm).
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alterations such as swelling, and decrease in number as well disruption of the cris-
tae with formation of large vesicles (Figure 3).
Figure 2. Electron micrograph of longitudinal slices of left ventricular cardiomyocytes of rats in the pravastatin group (PR).
Observe the increased concentration of intact mitochondria (m) and rare mitochondria with initial cristalysis (mc). The sarco-
meres (S) are well delineated by Z lines (Bar = 0.5µm).
Figure 3. Electron micrograph of longitudinal slices of left ventricular cardiomyocytes of rats in cold stress group (ST). Note
the increased concentration of mitochondrial lysis (m). The intercellular space between two cardiomyocytes is shown. The sar-
coplasmic membrane shows a notched edge (↓). It is possible to observe some myofilaments with evident discontinuity (*).
The head of the arrows (  ) shows the lacunar spaces (Bar = 0.8µm).
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In the pravastatin + stress group (PR+ST), cardiomyocytes with intact cells
were observed. The sarcoplasmic membrane, in the majority of images, had a
continuous and rectilinear appearance. The sarcoplasma replete of mitochondria
with varied forms and dimensions, distributed in an interposed manner between
myofilaments. Some lipid droplets were also observed near mitochondrial con-
glomerates. The myofilaments were normally arranged with some areas of dis-
continuity, showing a uniform periodicity of sarcomeres. The nucleus, generally
unique and central, showed a euchromatic pattern (Figure 4).
Morphometric analysis: The number and the mean of mitochondrial counting
profile with crystalysis in the cardiomyocytes of rats belonging to the four groups
were measured by three independent observers. The results are presented in
Tables I and II. The high index of intraclass correlation (R) observed varied
between 0.60 to 0.99, confirming the reliability of this method for determining
the difference between the groups (Table II). Table II showed for each animal, the
results of three observers, for considering the reproductibility.
Statistically significant differences among the groups were demonstrated
and they were complemented by a test of the difference among the means. The ST
group was  statistically different compared to the CON and PR groups (P < 0.05).
Figure 4. Electron micrograph of longitudinal slices of left ventricular cardiomyocytes of rats in the cold stress and pravasta-
tin pretreatment group (PR + ST). Note partial  view of two cardiomyocytes separated by a straight and intact sarcolemma (↓).
The intercellular space occupied by a capillary, showing a euchromatic nucleus and a red blood cell (*). The sarcolemmal
membrane is filled by a high concentration of mitochondria with some lipid droplets (I) and myofilaments forming well-
defined sarcomeres (S)  (Bar = 0.8µm).
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Table II.   Comparative Analysis of Mitochondrial Crystalysis
Profile Number
Groups
Photos CON PR ST PR+ST
1
2
3
4
5
6
6.7
6.0
6.0
4.7
9.3
9.3
5.7
17.7
4.0
13.0
14.3
11.0
58.3
64.7
64.0
89.3
67.3
48.3
21.3
16.3
13.0
12.0
16.7
17.3
Mean 7.0 10.95 65.3 16.1
The values represented in the columns express the mean result
between three independent observers in the control (CON),
pravastatin  (PR), stress (ST), and pravastatin + stress (PR + ST)
groups. Variance analysis was performed using the Kruskal-
Wallis method. Hc. = 7.82, Hcalc. = 17.61*, (*P < 0.005). Com-
parison of means: Zc. = 2.6 and  Zcalc. = 10.77** (**P < 0.05).
ES > CON; PR and PR+ ST.
Table I.   Values of Mitochondrial Profiles with Crystalysis for Six Photomicro-
graphs Analysed by Three Independent Observers (O1, O2, O3) in the Control
(CON), Pravastatin (PR), Stress (ST), and Pravastatin + Stress (PR+ST) Groups
Groups
Numbers CON PR ST PR+ST
O1 O2 O3 O1 O2 O3 O1 O2 O3 O1 O2 O3
1
2
3
4
5
6
8
8
6
6
8
7
6
5
6
4
10
10
6
5
6
4
10
11
9
18
6
13
13
9
4
18
3
13
13
12
4
17
3
13
17
12
58
64
64
90
70
48
58
65
64
90
66
48
59
65
64
88
66
49
20
17
13
13
17
18
20
16
13
13
17
19
24
16
13
10
16
15
Total 43 41 42 68 63 66 394 391 391 98 98 94
CON, R = 0.60, PR, R = 0.80, ST, R = 0.99, PR + ST, R= 0.82.
Table III.   Total Cholesterol (C) Values and Creatine Phosphokinase
(CPK) Enzyme Levels in the Control (CON), Pravastatin (PR), Stress
(ST), and Pravastatin+Stress (PR + ST) Groups
Groups
(n = 20)
C (mg/dL)
CPK (U/L)
CON
96±15
1833,3±739
PR
93±19
1522±374
ST
106±24
1708±300
PR+ST
99±12
1078±314
C: P > 0,05-not significant; CPK: P > 0,05-not significant.
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The PR+ST group  showed intermediate values between the CON and PR
groups, which was interpreted as partial protection of pravastatin during stress
induced by cold (Table II).
      The C and CPK levels among the groups were not statistically different
(Table III).
DISCUSSION
In the present study, cold was used as an alarmogen agent and pravastatin as
a pharmacological substance to verify possible myocardial protection. Pravasta-
tin is a drug belonging to a group of competitive inhibitors of HMG-coA reduc-
tase, and this enzyme has been implicated in cholesterol synthesis.18) It was
observed in this experiment that pravastatin in the short term neither reduced cho-
lesterol levels and nor provoked muscle damage as demonstrated by CPK mea-
surements (Table III).
It was observed that pretreatment of the rats with pravastatin submitted to
cold stress according to this methodology produced an evident  direct protective
effect on cardiomyocyte lesions demonstrated by mitochondrial ultrastructure
preservation. This result indicates that the effect of pravastatin on cardiomyocyte
protection is independent of cholesterol reduction since in the short term a reduc-
tion in cholesterol levels in the PR and PR+ST groups was not observed.
Different clinical trials have demonstrated  significant reductions in cardio-
vascular events, coronary events, and death due to ischemic heart disease with the
clinical use of HMG-coA reductase  inhibitors such as pravastatin.12,19-22)
Studies related to atherosclerosis regression in humans have reported differ-
ent and contrasting results ranging from a large decrease in clinical events to a
small reduction in the degree of coronary stenosis in coronary angiography stud-
ies. Physical regression of the atheroma may not be the main mechanism of
reduction in cardiac risk.23-26) This is  probably  due partially to a normalization of
vasomotor function dependent on endothelial cells.27-31)
Myocardial perfusion studies32-34) and endothelial function studies35,36) have
shown clinical and functional improvements before the detection of lesional ath-
erosclerotic  regression. They also showed an improvement in vasodilatory func-
tion of vascular endothelium at the level of  the coronary30,37,38) and peripheral
circulation39) through the use of HMG-coA reductase inhibitors alone or in com-
bination with antioxidant therapy.29,40)
Hemostatic and inflammatory processes are possibly affected by pravasta-
tin. It can reduce platelet aggregation activity by altering the cholesterol content
of the platelet membrane which modifies its fluidity.41) In this way, it can inhibit
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the interaction between platelets and fibrinogen and reduce the expression of
diverse agents involved in the coagulation process.42)
Pravastatin has anti-inflammatory effects, and promotes a blockade of mac-
rophage activation43) and  the formation of foam cells.43,44) More recently it was
demonstrated that the drug promotes in vitro inhibition of PDGF and also affects
the transduction intermediated by angiotensin II through the suppression of two
proto-oncogenes, c-jun and c-fos,45) indicating the possibility of inducing a
regression of myocardial hypertrophy through the blockade of independent sig-
naling in the reduction of cholesterol.46)
The protection of cardiomyocytes by pravastatin in this study most likely
occurred due to its action on the modulation of vascular relaxation mediated by
the endothelium. This improvement of local regulation of coronary arterial tonus
could be a factor in the ischemic process produced by stress. The clinical benefits
associated with pravastatin not explained by low density lipoprotein cholesterol
(LDL) reductions may be the result of an independent action of pravastatin on
endothelial nitric oxide synthase (e NOS) activation.47,48) Pravastatin stimulates
an increase in nitric oxide (NO) production by cultured endothelial cells similar
to the effects seen with acetylcholine.48)
It has been suggested that increased plasma LDL inhibits the active trans-
port of  L-arginine (L-ARG) by endothelial cells,49) uncoupling the L-ARG:
eNOS pathway and leading to superoxide anion production.50) Because both
superoxide anion and its reaction product NO, and peroxynitrite produce tissue
injury,51) it is possible that an indirect action of pravastatin  may be present to nor-
malize endothelial function by protecting the active arginine transport from injury
by LDL, thereby preventing the formation of both superoxide anion and perox-
ynitrite.50,51)
These results in animals subjected to cold stress and treated with pravastatin
showed a direct effect in addition to the global protection of cardiomyocytes.
There was a statistically significant specific reduction of mitochondrial crystaly-
sis, mainly related to the integrity of the mitochondria, since this was the para-
meter quantified to measure cardiomyocyte function during the exposure to cold.
At some point in this chain of events, pravastatin produced an interference culmi-
nating in such biomolecular action.
The protection of cardiomyocytes subjected to cold stress  under the exper-
imental conditions used in this present work can be included in the effects of
pravastatin. This knowledge may contribute to a better understanding of the fea-
sibility of using this agent in therapies of diverse clinical conditions involving
this kind of stressful situation.
These protective effects may be responsible for the clinical results observed
in the survival curves of the CARE study.12)
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These findings may possibly open new perspectives for more research and
may benefit experimental and clinical investigations. The present results indicate
the importance of pravastatin and its immediate effects on myocardial protection.
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